NCT07492927Recruiting
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Xijing Hospital
Start Date
3/12/2021
Completion Date
6/30/2027
Summary
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
1. Blood prostate-specific antigen PSA\>4ng/dl;
2. Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
3. The patient is willing to undergo prostate biopsy.
Exclusion Criteria:
1. Previous diagnosis of prostate cancer through prostate biopsy;
2. History of other malignant tumors in the past two years;
3. According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment
Conditions
Clinically Significant Prostate Cancer
Locations
Northwestern Memorial Hospital
Chicago, Illinois 60611
United States
The First Hospital of Lanzhou University
Lanzhou, Gansu
China
General Hospital of Ningxia Medical University
Yinchuan, Ningxia
China
Qinghai University Affiliated Hospital
Xining, Qinghai
China
Weinan Central Hospital
Weinan, Shaanxi
China
Shaanxi Provincial People's Hospital
Xi'an, Shaanxi
China
Xijing 986 Hospital
Xi'an, Shaanxi
China
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
Xianyang, Shaanxi
China
Yan'an University Affiliated Hospital
Yan’an, Shaanxi
China
Xijing Hospital
Xi'an, 710032
China